vs

Side-by-side financial comparison of Eventbrite, Inc. (EB) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $73.5M, roughly 1.0× Eventbrite, Inc.). Eventbrite, Inc. runs the higher net margin — -11.1% vs -121.9%, a 110.8% gap on every dollar of revenue. On growth, Eventbrite, Inc. posted the faster year-over-year revenue change (-3.9% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-60.9M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -7.7%).

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

EB vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.0× larger
HCAT
$74.7M
$73.5M
EB
Growing faster (revenue YoY)
EB
EB
+2.3% gap
EB
-3.9%
-6.2%
HCAT
Higher net margin
EB
EB
110.8% more per $
EB
-11.1%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$70.5M more FCF
HCAT
$9.6M
$-60.9M
EB
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-7.7%
EB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EB
EB
HCAT
HCAT
Revenue
$73.5M
$74.7M
Net Profit
$-8.2M
$-91.0M
Gross Margin
68.1%
Operating Margin
-12.4%
-115.3%
Net Margin
-11.1%
-121.9%
Revenue YoY
-3.9%
-6.2%
Net Profit YoY
2.5%
-340.3%
EPS (diluted)
$-0.08
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EB
EB
HCAT
HCAT
Q4 25
$73.5M
$74.7M
Q3 25
$71.7M
$76.3M
Q2 25
$72.8M
$80.7M
Q1 25
$73.8M
$79.4M
Q4 24
$76.5M
$79.6M
Q3 24
$77.8M
$76.4M
Q2 24
$84.6M
$75.9M
Q1 24
$86.3M
$74.7M
Net Profit
EB
EB
HCAT
HCAT
Q4 25
$-8.2M
$-91.0M
Q3 25
$6.4M
$-22.2M
Q2 25
$-2.1M
$-41.0M
Q1 25
$-6.6M
$-23.7M
Q4 24
$-8.4M
$-20.7M
Q3 24
$-3.8M
$-14.7M
Q2 24
$1.1M
$-13.5M
Q1 24
$-4.5M
$-20.6M
Gross Margin
EB
EB
HCAT
HCAT
Q4 25
68.1%
Q3 25
67.9%
52.6%
Q2 25
67.5%
Q1 25
66.9%
Q4 24
68.2%
Q3 24
68.5%
47.5%
Q2 24
70.9%
Q1 24
71.0%
Operating Margin
EB
EB
HCAT
HCAT
Q4 25
-12.4%
-115.3%
Q3 25
-1.3%
-22.9%
Q2 25
-8.7%
-46.0%
Q1 25
-13.2%
-25.4%
Q4 24
-10.2%
-22.0%
Q3 24
-11.5%
-17.9%
Q2 24
-7.6%
-20.8%
Q1 24
-8.8%
-30.5%
Net Margin
EB
EB
HCAT
HCAT
Q4 25
-11.1%
-121.9%
Q3 25
8.9%
-29.1%
Q2 25
-2.9%
-50.8%
Q1 25
-9.0%
-29.9%
Q4 24
-11.0%
-26.0%
Q3 24
-4.8%
-19.3%
Q2 24
1.3%
-17.8%
Q1 24
-5.2%
-27.6%
EPS (diluted)
EB
EB
HCAT
HCAT
Q4 25
$-0.08
$-1.29
Q3 25
$0.06
$-0.32
Q2 25
$-0.02
$-0.59
Q1 25
$-0.07
$-0.35
Q4 24
$-0.09
$-0.33
Q3 24
$-0.04
$-0.24
Q2 24
$0.01
$-0.23
Q1 24
$-0.05
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EB
EB
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$299.9M
$95.7M
Total DebtLower is stronger
$144.4M
$153.3M
Stockholders' EquityBook value
$179.1M
$245.8M
Total Assets
$647.2M
$502.6M
Debt / EquityLower = less leverage
0.81×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EB
EB
HCAT
HCAT
Q4 25
$299.9M
$95.7M
Q3 25
$91.5M
Q2 25
$97.3M
Q1 25
$342.0M
Q4 24
$441.5M
$392.0M
Q3 24
$24.7M
$387.3M
Q2 24
$56.7M
$308.3M
Q1 24
$113.7M
$327.8M
Total Debt
EB
EB
HCAT
HCAT
Q4 25
$144.4M
$153.3M
Q3 25
$174.9M
$153.1M
Q2 25
$241.3M
$153.0M
Q1 25
$241.0M
$382.9M
Q4 24
$240.7M
$382.4M
Q3 24
$240.4M
$345.0M
Q2 24
$358.7M
Q1 24
$358.2M
Stockholders' Equity
EB
EB
HCAT
HCAT
Q4 25
$179.1M
$245.8M
Q3 25
$189.1M
$331.9M
Q2 25
$177.2M
$347.5M
Q1 25
$173.3M
$376.8M
Q4 24
$170.2M
$365.2M
Q3 24
$179.8M
$355.0M
Q2 24
$176.2M
$357.0M
Q1 24
$184.1M
$357.2M
Total Assets
EB
EB
HCAT
HCAT
Q4 25
$647.2M
$502.6M
Q3 25
$744.6M
$587.1M
Q2 25
$784.1M
$616.2M
Q1 25
$812.3M
$891.5M
Q4 24
$752.3M
$858.9M
Q3 24
$817.4M
$813.0M
Q2 24
$894.5M
$691.7M
Q1 24
$952.2M
$695.1M
Debt / Equity
EB
EB
HCAT
HCAT
Q4 25
0.81×
0.62×
Q3 25
0.92×
0.46×
Q2 25
1.36×
0.44×
Q1 25
1.39×
1.02×
Q4 24
1.41×
1.05×
Q3 24
1.34×
0.97×
Q2 24
2.04×
Q1 24
1.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EB
EB
HCAT
HCAT
Operating Cash FlowLast quarter
$-60.8M
$9.9M
Free Cash FlowOCF − Capex
$-60.9M
$9.6M
FCF MarginFCF / Revenue
-82.8%
12.9%
Capex IntensityCapex / Revenue
0.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$17.6M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EB
EB
HCAT
HCAT
Q4 25
$-60.8M
$9.9M
Q3 25
$36.7M
$-464.0K
Q2 25
$-17.5M
$-9.0M
Q1 25
$59.4M
$280.0K
Q4 24
$-45.3M
$-3.5M
Q3 24
$44.6M
$6.2M
Q2 24
$-32.3M
$1.6M
Q1 24
$68.6M
$10.3M
Free Cash Flow
EB
EB
HCAT
HCAT
Q4 25
$-60.9M
$9.6M
Q3 25
$36.6M
$-719.0K
Q2 25
$-17.5M
$-9.2M
Q1 25
$59.4M
$-390.0K
Q4 24
$-45.3M
$-3.9M
Q3 24
$44.4M
$5.5M
Q2 24
$-32.4M
$1.3M
Q1 24
$68.2M
$10.1M
FCF Margin
EB
EB
HCAT
HCAT
Q4 25
-82.8%
12.9%
Q3 25
51.1%
-0.9%
Q2 25
-24.1%
-11.4%
Q1 25
80.4%
-0.5%
Q4 24
-59.2%
-4.9%
Q3 24
57.1%
7.2%
Q2 24
-38.3%
1.7%
Q1 24
79.1%
13.5%
Capex Intensity
EB
EB
HCAT
HCAT
Q4 25
0.0%
0.4%
Q3 25
0.0%
0.3%
Q2 25
0.0%
0.3%
Q1 25
0.1%
0.8%
Q4 24
0.0%
0.5%
Q3 24
0.2%
0.9%
Q2 24
0.1%
0.4%
Q1 24
0.4%
0.3%
Cash Conversion
EB
EB
HCAT
HCAT
Q4 25
Q3 25
5.76×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-30.37×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EB
EB

US$52.0M71%
Other$21.6M29%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons